Difference between revisions of "THYROID-TUMORS"
(Imported from text file) |
|||
| Line 6: | Line 6: | ||
<br/>3. Anaplastic: malignant, death in 6 months | <br/>3. Anaplastic: malignant, death in 6 months | ||
<br/> | <br/> | ||
<br/>4. Medullary: hyperplasia of parafollicular C cells + increased calcitonin production. 15% assoc. with MEN 2A/2B. MEN syndrome | <br/>4. Medullary: hyperplasia of parafollicular C cells + increased calcitonin production. 15% assoc. with MEN 2A/2B. | ||
<br/> | |||
<br/>5. MEN syndrome: overactive RET-proto-oncogene ⟹ overactive tyrosine kinase ⟹ uncontrolled cell signalling. | |||
Latest revision as of 02:29, 21 March 2023
SUMMARY
1. Papillary: most common, well-differentiated, benign
2. Follicular: mimics normal tissue, can be well-differentiated or can progress to capsular invasion
3. Anaplastic: malignant, death in 6 months
4. Medullary: hyperplasia of parafollicular C cells + increased calcitonin production. 15% assoc. with MEN 2A/2B.
5. MEN syndrome: overactive RET-proto-oncogene ⟹ overactive tyrosine kinase ⟹ uncontrolled cell signalling.
Reference(s)
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
